All Releases
Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs
Panbela to Participate in Upcoming Virtual Investor Conferences
Panbela Announces Research Agreement with Johns Hopkins University School of Medicine
Panbela Provides Update on Current Clinical Trial: Decision to Hold Administration of SBP-101
PBLA Completes Enrollment in Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer
SBP to Participate in the 11th Annual Craig-Hallum Alpha Select Conference
SBP Schedules Conference Call on Nov 12, 2020 to Report Q3 2020 Financial Results
SBP Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
SBP Appoints Jennifer K. Simpson, Ph.D., as President and CEO
- Company founder Michael T. Cullen, M.D. will continue to serve as Executive Chairman
SBP Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer
SBP Provides Business Update and Reports Operating Results for FY2019
- Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated
- Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in treatment-naïve patients with metastatic pancreatic cancer
SBP Initiates Search for CEO
Company founder Dr. Michael T. Cullen intends to continue to serve as Executive Chairman and will continue to serve as President and CEO until a successor is named
SBP Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium
- SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel
- Objective Response Rate (ORR) was 62% by RECIST criteria
- Study expansion in patients with pancreatic cancer planned to begin in Q2
View/download press release »
View/download poster presentation »
SBP Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium
Biotech Executive Arthur Fratamico Recently Joined Board of Directors
View/download press release »
View/download poster presentation »
SBP Provides a Business Update and Reports Q3 2019 Financial Results
- Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort planned
- New U.S. sites added in anticipation of further clinical development
- Company raised $3.1 million in new capital
SBP Provides a Business Update and Files Report for Q2 2019
- Enrollment in Third Cohort of PDA Combination Study is Encouraging
- Preliminary Efficacy Signals Improve with New Data Regarding Second Cohort
- Entire $2.3 million Owed under Convertible Notes Converted to Equity
SBP Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial
- Preliminary Efficacy Signals Seen with SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel
- DSMB Approves Enrollment of 3rd and Final Cohort
SBP Provides a Business Update and Files Report for Q1 2019
- Enrollment in Second Cohort of PDA Combination Study Completed
- New Funding Totaling $0.8 Million Secured
SBP Provides a Business Update and Files Report for Q3 2018
- Sun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with Metastatic Pancreatic Cancer
- Company announces leadership changes
- Results of new pancreatitis study presented at American Pancreatic Association meeting
SBP to Present Results of New Study at American Pancreatic Association Meeting
New study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” will be presented at the American Pancreatic Association meeting in Miami, FL on Nov. 1.
View/download press release »
View/download poster presentation »
SBP Announces Leadership Changes
- David B. Kaysen Steps Down as President, CEO and Board Member Effective October 31, 2018
- Michael T. Cullen MD, MBA, Executive Chairman, Elected President and CEO by Board of Directors Effective October 31, 2018
SBP Provides a Business Update and Files Report for Q2 2018
- First Patients Enrolled in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- Additional Funds Raised during Q2
SBP Presents Poster at PancreasFest in Pittsburgh PA
- Results of Phase 1 Safety Study of SBP-101 for Pancreatic Ductal Adenocarcinoma
- PancreasFest is an International Conference of Physicians and Scientists Focused on Pancreatic Diseases
View/download press release »
View/download poster presentation »
SBP Doses First Patients in 2nd Clinical Study of SBP-101
SUN BIOPHARMA, INC. DOSES FIRST PATIENTS IN SECOND CLINICAL STUDY OF SBP-101 FOR PANCREATIC DUCTAL ADENOCARCINOMA
- After Successful Completion of the Phase 1 Dose Escalation/Safety Study of SBP-101, New Combination Study Opens for Previously Untreated Metastatic Pancreatic Cancer Patients
- SBP-101 is a Proprietary Polyamine Analogue Targeted Specifically for Pancreatic Diseases
- SBP-101 was Invented by Emeritus Professor Raymond Bergeron at the University of Florida in Gainesville, Florida, USA with World-Wide Exclusive Rights Licensed to Sun BioPharma, Inc.
SBP Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study
SBP Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update
SBP Announces Completion of 5th Patient Cohort in the Dose Escalation Phase 1a Study of SBP-101 for Pancreatic Cancer
SBP Provides Phase 1 Trial Update; Patients Experience Early Signs of Efficacy
The NIH Awards SBP Grant to Study SBP-101 for the Treatment of Pancreatitis
SBP to Initiate 5th Patient Cohort in its Dose Escalation Phase 1 Study of SBP-101 for Pancreatic Cancer
SBP Receives DSMB Approval to Start 4th Patient Cohort in SBP-101 Dose Escalation Phase 1 Study
SBP Announces Effectiveness of its Registration Statement on Form S-1
SBP Announces Completion of 2nd Patient Cohort, Starts Recruitment of 3rd Cohort Patients
Sun BioPharma, Inc. Raises $2.0 Million Through Private Placement Transaction
Sun BioPharma Completes 1st Patient Cohort & Starts Recruitment of 2nd Cohort Patients in Dose Escalation Phase 1 Study
Sun BioPharma Provides Business Update and Reports Financial Results for Q1 2016
Dosing of First Patient in Phase 1 Clinical Study of SBP-101 for Pancreatic Cancer
Q3 2015 Earnings Release
Sun BioPharma Files Form 10-Q for Third Quarter 2015 and Provides Business Update
Compelling Preclinical Data on Sun BioPharma’s SBP-101 Presented at APA Annual Meeting
Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association (APA) Annual Meeting
Presentations to Focus on Pre-Clinical Data for Company’s Lead Development Candidate, SBP-101, for the Treatment of Pancreatic Diseases
Scott Kellen Appointed Chief Financial Officer of Sun BioPharma
Healthcare Executive Brings Extensive Public Company Financial Experience to Leadership Team
J. Robert Paulson and Jeffrey Mathiesen Appointed to Board of Directors
Two Experienced Healthcare Executives Join Board as Company Prepares to Enroll First Patient in Phase 1 Clinical Trial
David Kaysen Named President & CEO of Sun BioPharma
Healthcare Executive Brings Extensive Clinical & Public Markets Experience to Sun’s Management Team
Sun BioPharma Adopts OTCPink Symbol SNBP
Company’s clinical development program focuses on novel approach to treatment of pancreatic cancer
U.S. FDA Grants IND for SBP-101
APA 2015
Sun BioPharma will participate in the poster session at the American Pancreatic Association Annual Meeting on 4-7 November, 2015 in San Diego, CA.
For more information please visit their website at www.american-pancreatic-association.org
PancreasFest 2015
Sun BioPharma participated in the poster session at PancreasFest on 22-24 July 2015 in Pittsburgh, PA.
A joint meeting of physicians and scientists committed to learning and collaborating on translational studies of pancreatic diseases.
For more information, please visit their website at pancreasfest.com